VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company stated that the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. According to Volition, this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
Sepsis is a life-threatening condition that arises when the body's response to infection causes widespread inflammation, leading to organ dysfunction. Early detection is critical for improving outcomes, but current diagnostic methods often require centralized laboratory facilities. Volition's finger-prick test could enable rapid, decentralized testing, potentially reducing time to treatment and saving lives. The company's Nu.Q technology detects nucleosomes, which are DNA-protein complexes released into the bloodstream during cell death, a hallmark of sepsis and other diseases.
The announcement represents a significant step toward bringing epigenetic testing to point-of-care settings. Volition has been developing simple, cost-effective blood tests for early detection and monitoring of diseases, including cancers and conditions associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with additional offices in the U.S. and London.
For more details, the full press release is available at https://ibn.fm/ioEmu. Additional information about Volition can be found on its website at www.Volition.com.
